4.4 Article

Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features

Journal

HAEMATOLOGICA
Volume 98, Issue 7, Pages 1081-1088

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2013.085175

Keywords

-

Categories

Funding

  1. Leukaemia Lymphoma Research
  2. Kay Kendall Leukaemia Fund

Ask authors/readers for more resources

In childhood B-cell precursor acute lymphoblastic leukemia, cytogenetics is important in diagnosis and as an indicator of response to therapy, thus playing a key role in risk stratification of patients for treatment. Little is known of the relationship between different cytogenetic subtypes in B-cell precursor acute lymphoblastic leukemia and the recently reported copy number abnormalities affecting significant leukemia associated genes. In a consecutive series of 1427 childhood B-cell precursor acute lymphoblastic leukemia patients, we have determined the incidence and type of copy number abnormalities using multiplex ligation-dependent probe amplification. We have shown strong links between certain deletions and cytogenetic subtypes, including the novel association between RB1 deletions and intrachromosomal amplification of chromosome 21. In this study, we characterized the different copy number abnormalities and show heterogeneity of PAX5 and IKZF1 deletions and the recurrent nature of RB1 deletions. Whole gene losses are often indicative of larger deletions, visible by conventional cytogenetics. An increased number of copy number abnormalities is associated with NCI high risk, specifically deletions of IKZF1 and CDKN2A/B, which occur more frequently among these patients. IKZF1 deletions and rearrangements of CRLF2 among patients with undefined karyotypes may point to the poor risk BCR-ABL1-like group. In conclusion, this study has demonstrated in a large representative cohort of children with B-cell precursor acute lymphoblastic leukemia that the pattern of copy number abnormalities is highly variable according to the primary genetic abnormality.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study

Anthony Moorman, Ellie Butler, Emilio Barretta, Amy A. Kirkwood, Claire Schwab, Thomas Creasey, Daniel A. Leongamornlert, Elli Papaemmanuil, Pip Patrick, Laura Clifton-Hadley, Bela Patel, Tobias F. Menne, Andrew K. McMillan, Christine J. Harrison, Clare J. Rowntree, David Marks, Adele K. Fielding, Eleanor J. Ward, Katie Twentyman, Amir Enshaei

Summary: Chromosomal abnormalities have a significant prognostic impact on patients with B-cell precursor ALL, with specific abnormalities like KMT2A-AFF1, complex karyotype, and low hypodiploidy/near-triploidy associated with poor outcomes. Patients with BCR-ABL1 have similar outcomes to others, while JAK-STAT abnormalities are linked to a high relapse rate of 56%.

LEUKEMIA (2022)

Article Oncology

Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse

Zeljko Antic, Jiangyan Yu, Beat C. Bornhauser, Stefan H. Lelieveld, Cedric G. van der Ham, Simon van Reijmersdal, Lionel Morgado, Sarah Elitzur, Jean-Pierre Bourquin, Giovanni Cazzaniga, Cornelia Eckert, Mireia Camos, Rosemary Sutton, Helene Cave, Anthony Moorman, Edwin Sonneveld, Ad Geurts van Kessel, Frank N. van Leeuwen, Peter M. Hoogerbrugge, Esme Waanders, Roland P. Kuiper

Summary: Early relapses in BCP-ALL often arise from minor subclones at diagnosis. Understanding the therapeutic pressure driving these events may help develop improved therapies.

PEDIATRIC BLOOD & CANCER (2022)

Article Hematology

Activity and toxicity of intramuscular 1000 iu/m2 polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials

Jasmeet Sidhu, Ashish Narayan Masurekar, Manash Pratim Gogoi, Caroline Fong, Tasos Ioannou, Taha Lodhi, Catriona Parker, Jizhong Liu, Amy A. Kirkwood, Anthony Moorman, Kiranmoy Das, Nicholas J. Goulden, Ajay Vora, Vaskar Saha, Shekhar Krishnan

Summary: In successive UK clinical trials, polyethylene glycol-conjugated E. coli L-asparaginase was used in pediatric acute lymphoblastic leukemia patients. The treatment showed low toxicity but had wide interpatient variability. Therapeutic drug monitoring with individualized dosing could potentially optimize the treatment.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Article Biochemistry & Molecular Biology

High-resolution simulations of chromatin folding at genomic rearrangements in malignant B cells provide mechanistic insights into proto-oncogene deregulation

Daniel Rico, Daniel Kent, Nefeli Karataraki, Aneta Mikulasova, Rolando Berlinguer-Palmini, Brian A. Walker, Biola M. Javierre, Lisa J. Russell, Chris A. Brackley

Summary: This study used a predictive model to predict chromatin conformation of the proto-oncogene CCND1 in both healthy and malignant B cells, and found that genomic rearrangements involving CCND1 can lead to chromatin remodeling and oncogene activation.

GENOME RESEARCH (2022)

Article Oncology

Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial

Anthony V. Moorman, Grace Antony, Rachel Wade, Ellie R. Butler, Amir Enshaei, Christine J. Harrison, John Moppett, Rachael Hough, Clare Rowntree, Jeremy Hancock, Nicholas Goulden, Sujith Samarasinghe, Ajay Vora

Summary: The long-term outcomes of the UKALL2003 trial confirmed that treatment intensity can be adjusted based on minimal residual disease (MRD) stratification for patients with acute lymphoblastic leukemia. Low-risk patients can safely de-escalate therapy, while intensified therapy benefits high-risk patients. The time to cure is similar across risk groups.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia

Richard Gallon, Rachel Phelps, Leigh Betts, Christine Hayes, Dino Masic, Julie A. E. Irving, Ciaron McAnulty, Vaskar Saha, Ajay Vora, Katharina Wimmer, Jayashree Motwani, Christine Macartney, John Burn, Michael S. Jackson, Anthony Moorman, Mauro Santibanez-Koref

LEUKEMIA & LYMPHOMA (2023)

Meeting Abstract Hematology

Unmatched Whole-Genome Sequencing As a Clinical Tool for Hematological Neoplasms with Significant Utility in Cases with Tumor-in-Normal Contamination

Jesus Gutierrez-Abril, Daniel Leongamornlert, Neerav N. Shukla, Maria Luisa Sulis, Yangyu Zhou, Max F. Levine, Emilio Barretta, SooWah Lee, Juan E. Arango-Ossa, Gunes Gundem, Juan S. Medina-Martinez, Bela Patel Wrench, Anthony Moorman, Adele K. Fielding, Andrew L. Kung, Elli Papaemmanuil

BLOOD (2022)

Meeting Abstract Hematology

Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance

Amir Enshaei, Javier Martinez Martinez Elicegui, Esther Anguiano, Jude Gibson, Mirella Ampatzidou, Michael Doubek, Adele K. Fielding, Edoardo La Sala, Elizabeth Middleton, Anita W. Rijneveld, Amin T. Turki, Ajay Vora, Martin Zimmermann, Anthony Moorman

BLOOD (2022)

Meeting Abstract Hematology

Final Results from UKALL60+(NCT01616238), a UK National Cancer Research Institute Trial for Older People with De Novo Acute Lymphoblastic Leukaemia

Bela Patel Wrench, Amy A. Kirkwood, Krisztina Zuborne Alapi, Laura Clifton-Hadley, SooWah Lee, David Marks, Anthony Moorman, Nicholas J. Morley, Pip Patrick, Zaynab Rana, Clare J. Rowntree, John A. Snowden, Adele K. Fielding

BLOOD (2022)

Meeting Abstract Hematology

Dual Targeting of MDM2 and BCL2/Bclxl Demonstrates Potent Synergistic Activity in High-Risk Adult Acute Lymphoblastic Leukemia

Hayden L. Bell, Mankaran Singh, Helen J. Blair, Olaf Heidenreich, Frederik W. van Delft, Anthony Moorman, John Lunec, Julie Irving

BLOOD (2022)

Meeting Abstract Hematology

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Angus Hodder, Avijeet K. Mishra, Katherine Clesham, Susan Baird, Kaljit Bhuller, Ismail Bisho, Denise Bonney, Anna Castleton, Michelle Cummins, Emmy Dickens, Lindsay George, Sara Ghorashian, Brenda Gibson, Chris Hasley, Nicholas Heaney, Rachael E. Hough, Danielle Ingham, Galina Jigoulina, Katherine Lindsay, Donna Lancaster, Majid Madni, Andrea Malone, Bethany Mitchell, Anthony Moorman, John Moppett, Vanessa McLelland, Jayashree Motwani, Emma Nicholson, Caroline Osborne, Katharine Patrick, Lamia Samrin, Sanjay Tewari, Indu Rakesh Thakur, Sujith Samarasinghe, Ajay Vora, David O'Connor

BLOOD (2022)

Meeting Abstract Hematology

Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia

Daniel Leongamornlert, Jesus Gutierrez-Abril, SooWah Lee, Emilio Barretta, Thomas Creasey, Krisztina Zuborne Alapi, Max F. Levine, Juan E. Arango-Ossa, Juan S. Medina-Martinez, Amy A. Kirkwood, Laura Clifton-Hadley, Pip Patrick, David Jones, Adam P. Butler, Christine J. Harrison, Peter J. Campbell, Bela Patel Wrench, Anthony Moorman, Adele K. Fielding, Elli Papaemmanuil

BLOOD (2022)

Meeting Abstract Hematology

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

Anna Ostergaard, Amir Enshaei, Rob Pieters, Ajay Vora, Martin A. Horstmann, Gabriele Escherich, Bertil Johansson, Mats Heyman, Kjeld Schmiegelow, Peter M. Hoogerbrugge, Monique L. den Boer, Roland P. Kuiper, Anthony Moorman, Judith M. Boer, Frank N. van Leeuwen

BLOOD (2022)

Article Hematology

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

Anna ostergaard, Amir Enshaei, Rob Pieters, Ajay Vora, Martin A. Horstmann, Gabriele Escherich, Bertil Johansson, Mats Heyman, Kjeld Schmiegelow, Peter M. Hoogerbrugge, Monique L. den Boer, Roland P. Kuiper, Anthony V. Moorman, Judith M. Boer, Frank N. van Leeuwen

Summary: IKZF1 deletions have a significant negative impact on the survival of patients with ETV6::RUNX1 and high hyperdiploid ALL. The presence of IKZF1 deletions is associated with lower event-free survival rates, higher minimal residual disease values, and higher relapse rates in both ETV6::RUNX1 and high hyperdiploid ALL. Stratifying patients by minimal residual disease may not be sufficient for predicting outcomes in high hyperdiploid ALL, suggesting the need for additional risk stratification.

HEMASPHERE (2023)

Article Hematology

In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial

David Marks, Laura Clifton-Hadley, Mhairi Copland, Jiaull Hussain, Tobias F. Menne, Andrew McMillan, Anthony Moorman, Nicholas Morley, Dina Okasha, Bela Patel, Pip Patrick, Michael N. Potter, Clare J. Rowntree, Amy A. Kirkwood, Adele K. Fielding

Summary: This study evaluated the activity and safety of reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation (HSCT) in patients older than 40 years with acute lymphoblastic leukaemia. The results showed that this transplantation method provided good disease control with moderate graft-versus-host disease (GVHD) and achieved better-than-expected event-free survival and overall survival in this high-risk population.

LANCET HAEMATOLOGY (2022)

No Data Available